BIOLEX THERAPEUTICS, INC.
|BIOLEX THERAPEUTICS, INC. Patent applications|
|Patent application number||Title||Published|
|20120276086||MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES - The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30||11-01-2012|
|20120258491||EXPRESSION OF BIOLOGICALLY ACTIVE POLYPEPTIDES IN DUCKWEED - Methods, nucleic acid sequences, and transformed duckweed plant or duckweed nodule cultures for the expression and the secretion of biologically active polypeptides from genetically engineered duckweed are provided. Expression of recombinant polypeptides in duckweed is improved by modifying the nucleotide sequence of the expression cassette encoding the polypeptide for improved expression in duckweed. Recovery of biologically active polypeptides from duckweed is improved by linking the biologically active polypeptide to a signal peptide that directs the secretion of the polypeptide into the culture medium.||10-11-2012|
|20120190004||METHODS AND COMPOSITIONS FOR THE CRYOPRESERVATION OF DUCKWEED - The present invention describes methods for the cryopreservation of duckweed plants and duckweed plant tissues. The methods comprise freezing a dehydrated duckweed frond colony to a cryopreservative temperature to obtain a frozen frond colony comprising at least one cryopreserved duckweed plant or a cryopreserved duckweed plant tissue. The method can comprise a dehydration step whereby a duckweed frond colony is dehydrated, and in some embodiments, can further comprise a dormancy-induction step prior to or during the dehydration step. The method further can further comprise a recovery step, wherein the frozen frond colony is thawed and a viable duckweed plant or duckweed plant tissue is recovered. Cryopreserved duckweed plants and duckweed plant tissues, and viable duckweed plants and duckweed tissues recovered therefrom are also provided. In some embodiments, the duckweed frond colony, duckweed plant, and duckweed tissue comprise a heterologous polynucleotide of interest, which can encode a heterologous polypeptide of interest.||07-26-2012|
|20110250177||ALPHA INTERFERON VARIANTS - The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α-2b-interferon. The invention encompasses these biologically active variant α-interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant α-interferon polypeptides and a pharmaceutically acceptable carrier.||10-13-2011|
|20110144308||COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS - Methods for altering the N-glycosylation pattern of proteins in higher plants are provided. The methods comprise introducing into the plant a recombinant construct that provides for the inhibition of expression of α1,3-fucosyltransferase (FucT) and β1,2-xylosyltransferase (XylT) in a plant. Use of these constructs to inhibit or suppress expression of both of these enzymes, and isoforms thereof, advantageously provides for the production of endogenous and heterologous proteins having a “humanized” N-glycosylation pattern without impacting plant growth and development. Stably transformed higher plants having this protein N-glycosylation pattern are provided. Glycoprotein compositions, including monoclonal antibody compositions, having substantially homogeneous glycosylation profiles, and which are substantially homogeneous for the G0 glycoform, are also provided.||06-16-2011|
|20100186126||EXPRESSION OF PLASMINOGEN AND MICROPLASMINOGEN IN DUCKWEED - The present invention provides methods and compositions for the production of recombinant plasminogen, microplasminogen, and fragments thereof in a duckweed expression system. It is the novel finding of the present invention that a duckweed expression system may be used to produce high levels of plasminogen and microplasminogen. The duckweed-produced plasminogen and microplasminogen can be activated to produce a polypeptide having protease activity. Thus, the invention encompasses methods for the expression of plasminogen, microplasminogen, and fragments thereof in duckweed, duckweed plants that are transformed with expression cassettes for the expression of plasminogen, microplasminogen, and fragments thereof, and nucleic acids comprising nucleotide sequences encoding plasminogen, microplasminogen, and fragments thereof, where these nucleotide sequences are modified to enhance their expression in duckweed.||07-22-2010|
|20100074868||Controlled Release Compositions for Interferon Based on PEGT/PBT Block Copolymers - The invention discloses a pharmaceutical composition for the controlled release of relatively toxic active compounds, in particular for bioactive proteins from the class of interferons. The composition comprises a biodegradable block copolymer constructed from poly(ethylene glycol) terephthalate (PEGT) and poly(butylene terephthalate) (PBT). The composition is provided in the form of injectable microparticles, of an injectable liquid which may have self-gelling properties, or of a solid implant. The invention further provides a pharmaceutical kit comprising the composition, methods for preparing the composition, and the pharmaceutical uses relating thereto.||03-25-2010|
|20100043099||EXPRESSION CONTROL ELEMENTS FROM THE LEMNACEAE FAMILY - Compositions and methods for regulating expression of nucleotide sequences of interest in a plant are provided. Compositions include novel nucleic acid molecules, and variants and fragments thereof, for expression control elements isolated from the Lemnaceae ubiquitin, r-histone and chitinase genes. A method for expressing a nucleotide sequence of interest in a plant using the expression control elements disclosed herein is further provided. The method includes introducing into a plant or plant cell or nodule an expression construct comprising an expression control element of the present invention operably linked to a nucleotide sequence of interest. In particular, the compositions and methods find use in enhancing expression of nucleotide sequences of interest in duckweed. Also provided is a novel Lemnaceae signal peptide-encoding sequence and the signal peptide encoded thereby. Where an expression construct of the invention is designed to express a polypeptide of interest, this novel signal peptide-encoding sequence can be included within the expression construct of the invention to provide for extracellular secretion of the encoded polypeptide of interest.||02-18-2010|
|20090060921||GLYCAN-OPTIMIZED ANTI-CD20 ANTIBODIES - Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.||03-05-2009|
Patent applications by BIOLEX THERAPEUTICS, INC.